

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb Pharmaceuticals (nivolumab, ipilimumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer Laryngectomee Trust • Cancer52 • Changing Faces • Get-A-Head • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Let's Face it • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Mouth Cancer Foundation • Muslim Council of Britain • National Association of Laryngectomee Clubs • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care • The Swallows – Head & Neck Cancer Support Group <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Head and Neck Oncologists • British Association of Head and Neck Oncology Nurses • British Association of Oral and Maxillofacial Surgeons 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • A A H Pharmaceuticals (cisplatin) • Accord Healthcare (carboplatin, cisplatin, fluorouracil) • Consilient Health (carboplatin, fluorouracil) • Fresenius Kabi Oncology (carboplatin) • Hospira UK (carboplatin, cisplatin, fluorouracil) • Medac UK (fluorouracil) • Medac GmbH (fluorouracil) • Merck Serono (cetuximab) • Pfizer (carboplatin, cisplatin, fluorouracil) • Sandoz (cisplatin) • Teva UK (carboplatin, cisplatin)

Stakeholder list for the proposed technology appraisal of nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck ID1429. Issue date: July 2019.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association of Otorhinolaryngologists • British Dental Health Foundation • British Dietetic Association – Oncology Specialist Group • British Geriatrics Society • British Institute of Radiology • British Oculoplastic Surgery Society • British Psychosocial Oncology Society • British Skull Base Society • British Society of Interventional Radiology • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Southport and Formby CCG • NHS Stockport CCG • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Ear, Nose and Throat Disorders Group • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Oracle Cancer Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.